Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
LABD ETF: A Leveraged Inverse Biotech Tool for Short-Term Tactical Trading

LABD ETF: A Leveraged Inverse Biotech Tool for Short-Term Tactical Trading

Key Takeaways

  • LABD is a leveraged inverse exchange-traded fund (ETF) that seeks to deliver three times (3X) the opposite of the daily performance of the S&P Biotechnology Select Industry Index.
  • The fund is issued by Direxion and was launched on May 28, 2015; it is managed by Rafferty Asset Management, LLC.
  • LABD is designed for short-term, tactical traders, not long-term buy-and-hold investors, because its leverage resets daily.
  • The fund is non-diversified and gains exposure primarily through derivatives such as swaps, futures, and short positions rather than by directly owning biotech stocks.
  • Its bull counterpart is the Direxion Daily S&P Biotech Bull 3X ETF (LABU).

Getting Started with LABD

LABD, officially the Direxion Daily S&P Biotech Bear 3X ETF, is a specialized exchange-traded fund built for traders who want aggressive, short-term "bearish" exposure to the U.S. biotechnology sector. Rather than investing in biotech companies to benefit from their success, LABD is engineered to rise when biotechnology stocks fall—and to do so at three times the magnitude of the daily move.

This makes LABD very different from a conventional ETF. It is a trading instrument, not a long-term portfolio building block. Investors follow it for its leverage, its inverse exposure, and its role in hedging or speculating on short-term moves in one of the stock market's most volatile sectors. When I first looked into its mechanics, I also checked this using Tickeron’s AI Screener to see how it stacks up against similar leveraged products.

ETF Overview and Investment Strategy

LABD seeks daily investment results, before fees and expenses, of 300% of the inverse (the opposite) of the daily performance of the S&P Biotechnology Select Industry Index. In practical terms, if that index declines 1% in a single trading day, the fund aims to gain roughly 3%; if the index rises 1%, the fund aims to lose roughly 3%.

The underlying index is a modified equal-weighted benchmark designed to measure the performance of the biotechnology sub-industry, as classified under the Global Industry Classification Standard (GICS). Because it is equal-weighted rather than market-cap-weighted, the index gives proportionally more weight to smaller and mid-sized biotech companies than a cap-weighted benchmark would, which contributes to its historically higher volatility. From what I see, that equal-weight approach is one reason the fund can move so sharply on sector news.

LABD is a passively managed fund that pursues its leveraged inverse objective through derivatives. Under normal circumstances, the fund invests at least 80% of its net assets in financial instruments—including swap agreements, futures contracts, and short positions—that, in combination, provide 3X daily inverse exposure to the index. As a result, its actual portfolio holdings consist mainly of cash, U.S. Treasury instruments, and money-market funds used as collateral, alongside the swap and short positions that generate the inverse returns. Reported holdings commonly include institutional cash-management and Treasury funds from firms such as Goldman Sachs and BNY Mellon (Dreyfus).

The fund is issued by Direxion, a firm known for leveraged and inverse ETFs, and is managed by Rafferty Asset Management, LLC. LABD carries an expense ratio of roughly 1% (approximately 0.95% to 1.07%, depending on the reporting period), which is typical for leveraged products but higher than plain-vanilla index ETFs. It is non-diversified, meaning it can concentrate its positions more heavily than a diversified fund.

Why Investors Follow LABD

LABD attracts attention primarily because of its leverage and its inverse sector exposure. Biotechnology is a uniquely volatile corner of the market, where individual drug approvals, clinical trial results, and regulatory decisions can move entire indices sharply in a single session. For traders with a bearish short-term view on biotech, LABD offers a way to amplify that view without shorting individual stocks.

The fund also serves a hedging role. An investor with broad biotechnology holdings might use a small, temporary position in LABD to help offset short-term declines. Its heavily traded nature and its pairing with the bullish LABU give traders a readily available way to express views in both directions. The same underlying index is tracked by well-known unleveraged funds such as the SPDR S&P Biotech ETF (XBI), which some traders reference for context on the sector's broader market position and portfolio holdings. I’m watching this closely because the pairing with LABU provides a clean two-sided toolkit.

Risks and Important Considerations

LABD is among the riskier products available to individual investors, and its key risks stem directly from its design:

  • Daily reset and compounding risk: The fund's 3X inverse objective applies to a single day only. Because leverage resets each trading day, returns over periods longer than one day can diverge significantly from three times the inverse of the index's cumulative return, especially in choppy, sideways markets.
  • Volatility: Leveraged inverse products can experience large, rapid losses. Adverse moves are magnified to the same degree as favorable ones.
  • Derivatives and counterparty risk: LABD relies on swaps and other derivatives to achieve its exposure, which introduces counterparty and financing considerations not present in funds that own stocks directly.
  • Sector concentration: The fund is entirely focused on biotechnology, so it is highly sensitive to industry-specific events such as drug approvals, patent litigation, regulatory changes, and funding conditions for early-stage companies.
  • Costs: The roughly 1% expense ratio, combined with the costs of daily rebalancing and leverage, can erode returns over time.

Direxion itself cautions that leveraged and inverse ETFs are not suitable for all investors and should generally be used only by those who understand leverage risk and actively manage their positions.

Integrating AI Tools into My Workflow

In my own research process, Tickeron’s AI Screener has become a regular part of how I evaluate leveraged and inverse ETFs. It lets me apply technical indicators, volatility filters, and trend signals to quickly compare products like LABD against peers or the broader market. This helps surface ideas that fit short-term strategies without sifting through thousands of securities manually. The platform’s customizable options make it straightforward to focus on sectors or risk profiles that match what I’m analyzing at the moment.

Conclusion

LABD occupies a distinct niche in the ETF landscape. It offers traders a liquid, leveraged way to bet against the daily direction of U.S. biotechnology stocks, a sector known for sharp swings. Its value lies in short-term tactical use—whether for speculation or temporary hedging—rather than as a long-term holding. For investors who understand its daily-reset mechanics and accept its elevated risk, LABD remains a widely used tool for navigating one of the market's most dynamic industries.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LABD

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Momentum Indicator for LABD turns positive, indicating new upward trend

LABD saw its Momentum Indicator move above the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 85 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for LABD just turned positive on November 16, 2026. Looking at past instances where LABD's MACD turned positive, the stock continued to rise in 49 of 52 cases over the following month. The odds of a continued upward trend are 90%.

LABD moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LABD crossed bullishly above the 50-day moving average on November 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +10.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABD advanced for three days, in 246 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 141 of 156 cases where LABD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

LABD broke above its upper Bollinger Band on November 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests at least 80% of the fund’s net assets in financial instruments, including swap agreements, futures contracts, or short positions, that, in combination, provide 3X daily inverse (opposite) or short exposure to the index or to ETFs that track the index, consistent with the fund’s investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the GICS. The fund is non-diversified.
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.